Skip to main content
رجوع
NVO logo

Novo Nordisk A/S

جودة البيانات: 100%
ذروة بيع
NVO
NYSE Healthcare Biotechnology
KWD 36.89
▲ KWD 0.07 (0.19%)
القيمة السوقية: 163.94B
مُدرج أيضًا باسم NONOF OTC
نطاق اليوم
KWD 36.55 KWD 37.20
نطاق 52 أسبوعًا
KWD 35.85 KWD 81.44
حجم التداول
15,255,543
متوسط 50 يوم / 200 يوم
KWD 48.31 / KWD 54.90
الإغلاق السابق
KWD 36.82

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 1.7 0.3
P/B 0.8 2.9
ROE % 58.4 3.7
Net Margin % 33.1 3.8
Rev Growth 5Y % 20.5 10.0
D/E 0.7 0.2

السعر المستهدف للمحللين

Hold
KWD 47.000 +27.4%
Low: KWD 42.000 High: KWD 54.000
مكرر الربحية المستقبلي
1.8
ربحية السهم المستقبلية
KWD 20.820
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
290 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 28.012
KWD 25.651 – KWD 31.354
360 B 5
FY2029 KWD 25.762
KWD 23.591 – KWD 28.835
340 B 2
FY2028 KWD 23.257
KWD 21.297 – KWD 26.031
320 B 5

النقاط الرئيسية

Revenue grew 20.53% annually over 5 years — strong growth
ROE of 58.36% indicates high profitability
Net margin of 33.14% shows strong profitability
Generating 28.99B in free cash flow
P/E of 1.66 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 18.19%

النمو

Revenue Growth (5Y)
20.53%
Revenue (1Y)2.34%
Earnings (1Y)-2.46%
FCF Growth (3Y)-35.65%

الجودة

Return on Equity
58.36%
ROIC29.96%
Net Margin33.14%
Op. Margin43.69%

الأمان

Debt / Equity
0.67
Current Ratio0.80
Interest Coverage19.92

التقييم

P/E Ratio
1.66
P/B Ratio0.84
EV/EBITDA2.07
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 2.34% Revenue Growth (3Y) 13.12%
Earnings Growth (1Y) -2.46% Earnings Growth (3Y) 8.49%
Revenue Growth (5Y) 20.53% Earnings Growth (5Y) 19.84%
Profitability
Revenue (TTM) 297.20B Net Income (TTM) 98.50B
ROE 58.36% ROA 18.14%
Gross Margin 80.34% Operating Margin 43.69%
Net Margin 33.14% Free Cash Flow (TTM) 28.99B
ROIC 29.96% FCF Growth (3Y) -35.65%
Safety
Debt / Equity 0.67 Current Ratio 0.80
Interest Coverage 19.92 Dividend Yield 0.03%
Valuation
P/E Ratio 1.66 P/B Ratio 0.84
P/S Ratio 0.55 PEG Ratio 8.49
EV/EBITDA 2.07 Dividend Yield 0.03%
Market Cap 163.94B Enterprise Value 268.43B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 297.20B 290.40B 232.26B 176.95B 140.80B
Net Income 98.50B 100.99B 83.68B 55.53B 47.76B
EPS (Diluted) 23.03 22.63 18.62 12.22 10.37
Gross Profit 238.77B 245.88B 196.50B 148.51B 117.14B
Operating Income 129.83B 128.34B 102.57B 74.81B 58.64B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 542.90B 465.80B 314.49B 241.26B 194.51B
Total Liabilities 348.86B 322.31B 207.93B 157.77B 123.76B
Shareholders' Equity 194.05B 143.49B 106.56B 83.49B 70.75B
Total Debt 130.96B 102.79B 27.01B 25.78B 26.65B
Cash & Equivalents 26.46B 15.66B 14.39B 12.65B 10.72B
Current Assets 172.45B 160.90B 139.65B 108.19B 85.60B
Current Liabilities 215.66B 217.53B 169.66B 120.94B 99.52B

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 24, 2026